The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign is proud to announce its 2013 global Campaign for Breast Cancer Awareness Month and beyond. The 2013 theme, “Let’s Defeat Breast Cancer. We’re Stronger Together.”, is a call-to-action that will serve to shift public focus from awareness to increased action, advancing us further towards eradicating breast cancer from our lives. To date, The BCA Campaign has raised more than $48 million to support global research, education and medical services. This year’s BCA Campaign is committed to raising $5 million to support breast cancer research, education and medical services worldwide. Action doesn’t happen alone. When we join together…We’re Stronger Together.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63597-estee-lauder-elizabeth-hurley-breast-cancer-aware-campaign-aware-action
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer
“You have cancer.” Those three words are among the most dreaded and powerful a person can hear. In the case of Tony Harnell, the diagnosis of thyroid cancer was doubly frightening.
A vocalist/songwriter with a four-octave range, Harnell had toured in the U.S. with likes of Stryper, Twisted Sister and Great White and appeared on stages worldwide, entertaining legions of fans as lead singer with hard-rock band TNT.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62578-american-college-endocrinology-tony-harnell-advocate-thyroid-cancer-aware
Today’s superheroes don’t drive a Batmobile or fly through the air faster than the speed of light. Their capes are white lab coats and their superpower is the ability to cure. They are men and women researching cures for childhood cancer – the leading cause of death by disease in children under the age of 15 in the U.S.1- which is vastly underfunded.2
Starting today, Northwestern Mutual is giving consumers the chance to honor childhood cancer researchers and kids who are fighting cancer, by raising research funds through a new Facebook campaign, Heroes for a Cure. The Northwestern Mutual campaign aims to raise $50,000 – equal to 1,000 hours of research – in September, which is National Childhood Cancer Month.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59532-northwestern-mutual-launches-heroes-for-cure-campaign-fight-child-cancer
Global health service company Cigna is on a mission: to get HopeLab’s cancer-fighting game app Re-Mission 2: Nanobot’s Revenge onto the phones and tablets of every young cancer patient in the world. The free app is available for Android and iOS (Apple) mobile devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/62267-cigna-hopelab-re-mission-2-mobile-app
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
The USPSTF today issued a draft recommendation giving its second highest approval rating for CT screening for lung cancer for those at high risk, a move that if approved in final form, will trigger Medicare and insurance coverage and bring about a dramatic drop in the leading cause of cancer deaths.
Today, LCA also launched its Risk Navigator tool – www.AtRiskForLungCancer.org. Additionally, it expanded the hours of its support line – (800) 298-2436 – operating 8 a.m. to 7 p.m. EST. LCA will also launch a national educational advertising campaign in September to encourage the public to know their risk for lung cancer.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62719-lung-cancer-alliance-uspstf-recommends-ct-screening-for-lung-cancer
Team for Life - Fighting Cancer, Giving Hope
Lazarex Cancer Foundation (www.lazarex.org) is a 501(c)(3) non profit that was founded by Dana Dornsife, who is also President of the organization. She became a cancer advocate when her brother-in-law Mike was diagnosed with pancreatic cancer in 2003 as she searched for options that would buy Mike and his family some additional time. Her dedication enabled Mike to live long enough so that his youngest daughter would have real memories of him, which she could keep throughout her life
Pain can negatively affect a person’s quality of life and impede recovery from illness or injury. Recent research compiled by the American Massage Therapy Association (AMTA) suggests that massage can be a helpful pain management strategy for manually controlling symptoms in people suffering metastatic cancer and rheumatoid arthritis, among other illnesses, as well as post-cardiac surgery pain.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61665-amta-massage-therapy-for-pain-relief-cancer-arthritis-post-cardiac-surgery
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
